Aptevo Therapeutics Inc. (APVO): Total Assets
$27.19M
As of 2025-12-31
$14.52M
As of 2026-06-30
-7.4%
3-year compound annual growth
-12.7%
5-year compound annual growth
-14.3%
10-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $27.19M | +74.4% | 2026-03-26, Balance as of period end |
| 2024-12-31 | $15.59M | -37.2% | 2026-03-26, Balance as of period end |
| 2023-12-31 | $24.84M | -27.4% | 2025-02-14, Balance as of period end |
| 2022-12-31 | $34.22M | -39.6% | 2024-03-05, Balance as of period end |
| 2021-12-31 | $56.60M | +5.7% | 2023-03-30, Balance as of period end |
| 2020-12-31 | $53.55M | +0.3% | 2022-03-24, Balance as of period end |
| 2019-12-31 | $53.41M | -20.9% | 2021-03-31, Balance as of period end |
| 2018-12-31 | $67.49M | -42.3% | 2020-03-25, Balance as of period end |
| 2017-12-31 | $117.01M | +27.4% | 2019-03-18, Balance as of period end |
| 2016-12-31 | $91.86M | n/a | 2018-03-13, Balance as of period end |
| 2016-06-30 | $133.47M | n/a | 2017-03-31, Balance as of period end |
| 2016-03-31 | $127.92M | n/a | 2017-03-31, Balance as of period end |
| 2015-12-31 | $127.77M | n/a | 2017-03-31, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Aptevo Therapeutics Inc. (APVO) | 2025-12-31 | $27.19M | +74.4% |
| TuHURA Biosciences, Inc. (HURA) | 2025-12-31 | $27.35M | +37.0% |
| Skye Bioscience, Inc. (SKYE) | 2025-12-31 | $28.31M | -61.1% |
| BeyondSpring Inc. (BYSI) | 2025-12-31 | $25.93M | -24.4% |
| Biofrontera Inc. (BFRI) | 2025-12-31 | $28.56M | +29.2% |
| Elicio Therapeutics, Inc. (ELTX) | 2025-12-31 | $25.86M | -8.2% |
| Neuphoria Therapeutics Inc. (NEUP) | 2026-06-30 | $28.71M | +0.4% |
| CASI Pharmaceuticals, Inc. (CASIF) | 2025-12-31 | $25.65M | -52.2% |
| Onconetix, Inc. (ONCO) | 2025-12-31 | $24.93M | -11.5% |
Compare APVO, HURA, SKYE, BYSI side by side · Screen every company in Pharmaceutical Preparations ↗